X
REGN icon

Xponance’s Regeneron Pharmaceuticals REGN Stock Holding History

Xponance’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.3M Buy
18,063
+50
+0.3% +$34K 0.07% 223
2026
Q1 		$13.9M Buy
18,013
+2,377
+15% +$1.82M 0.1% 172
2025
Q4 		$12.1M Buy
15,636
+362
+2% +$246K 0.09% 177
2025
Q3 		$8.59M Sell
15,274
-591
-4% -$334K 0.07% 220
2025
Q2 		$8.33M Sell
15,865
-402
-2% -$224K 0.07% 223
2025
Q1 		$10.3M Sell
16,267
-5
-0% -$3.44K 0.1% 164
2024
Q4 		$11.6M Buy
16,272
+482
+3% +$405K 0.11% 152
2024
Q3 		$16.6M Buy
15,790
+289
+2% +$322K 0.16% 102
2024
Q2 		$16.3M Sell
15,501
-28
-0.2% -$27.1K 0.17% 96
2024
Q1 		$14.9M Buy
15,529
+1,153
+8% +$1.1M 0.16% 116
2023
Q4 		$12.6M Buy
14,376
+852
+6% +$702K 0.15% 120
2023
Q3 		$11.1M Sell
13,524
-1,062
-7% -$835K 0.15% 117
2023
Q2 		$10.5M Sell
14,586
-795
-5% -$613K 0.14% 120
2023
Q1 		$12.6M Buy
15,381
+432
+3% +$326K 0.18% 104
2022
Q4 		$10.8M Buy
14,949
+2,018
+16% +$1.49M 0.17% 115
2022
Q3 		$8.91M Buy
12,931
+502
+4% +$316K 0.17% 111
2022
Q2 		$7.35M Sell
12,429
-973
-7% -$632K 0.15% 123
2022
Q1 		$9.36M Buy
13,402
+202
+2% +$128K 0.16% 112
2021
Q4 		$8.34M Buy
13,200
+6,838
+107% +$4.2M 0.13% 138
2021
Q3 		$3.85M Sell
6,362
-462
-7% -$287K 0.07% 217
2021
Q2 		$3.81M Sell
6,824
-7,731
-53% -$3.92M 0.07% 228
2021
Q1 		$6.89M Sell
14,555
-40
-0.3% -$19.5K 0.15% 134
2020
Q4 		$7.05M Sell
14,595
-7,067
-33% -$3.81M 0.15% 119
2020
Q3 		$12.1M Sell
21,662
-1,491
-6% -$904K 0.3% 64
2020
Q2 		$14.4M Buy
+23,153
New +$13.1M 0.37% 55

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Xponance's REGN Position: Q2 2026 in Review

Xponance increased its Regeneron Pharmaceuticals (REGN) stake by 0.28% in Q2 2026, buying an estimated $34K and bringing the position to 18,063 shares worth $11.3M. The position accounts for 0.07% of the portfolio, ranked #223.

Xponance first reported a position in REGN in Q2 2020 and has held it in 25 quarters since. The position peaked at $16.6M in Q3 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Xponance held 18,063 shares of Regeneron Pharmaceuticals worth $11.3M as of Q2 2026.
  • Xponance bought 50 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $34K.
  • Regeneron Pharmaceuticals made up 0.07% of Xponance's portfolio in Q2 2026, its #223 holding.
  • Xponance first reported a position in Regeneron Pharmaceuticals in Q2 2020 and has held it in 25 quarters since.
  • Xponance's Regeneron Pharmaceuticals position peaked at $16.6M in Q3 2024.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.